The Food and Drug Administration has authorized four more flavored nicotine pouches for sale in the United States, and two of the country's largest health advocacy organizations objected the same day.
The FDA announcement covers products made by Helix Innovations, an Altria affiliate, and sold under the on! brand: Rich Berry 2 milligrams, Cappuccino 2 milligrams, Cappuccino 4 milligrams and Autumn Spice 2 milligrams. The agency has now authorized 30 nicotine pouch products in total.
For parents, the decision is less a warning than a signal about direction. Nicotine pouches are small, odorless and tucked between the lip and gum, which makes them far harder to notice at home or in a classroom than a vape. Every expansion of the authorized flavor list widens the set of products a teenager might encounter, and berry, cappuccino and autumn spice are not flavors anyone associates with tobacco.
The Agency's Reasoning Rests on Switching, Not on Safety
FDA did not describe these products as safe, and its stated basis deserves to be represented accurately.
The agency said its evaluation found the new products contain lower levels of most harmful and potentially harmful constituents when compared with other oral and smokeless tobacco products, with many of those constituents too low to be quantified. For adults 21 and older who use smokeless tobacco or smoke cigarettes, FDA said switching completely to authorized nicotine pouches may reduce exposure to many harmful chemicals.
FDA also attached an important condition: switching must be complete, because dual use does not deliver the same degree of risk reduction. The agency states elsewhere that all tobacco products are harmful and potentially addictive, and that people who do not use tobacco should not start.
The legal standard is a population-level test. To authorize a new tobacco product, FDA must find sufficient evidence that it offers greater benefits to population health than risks, weighing benefits to adults who switch against risks to youth and non-users.
The Youth Numbers Are More Complicated Than Either Side Suggests
Both the concern and the reassurance in this debate rest on the same dataset, and the honest reading sits between them.
FDA's analysis of the 2025 National Youth Tobacco Survey found that about 2 million students, or 7.2 percent of middle and high schoolers, reported current use of any tobacco product. E-cigarettes led at 5.2 percent. Nicotine pouches came second at 1.7 percent. FDA characterized youth pouch use as low overall and stable during 2024 to 2025, while noting that use among high school students rose over the longer 2022 to 2025 period.
A separate analysis published in Pediatrics by Stanton Glantz reached a different framing from the same survey. It noted that pouches were the only category that increased, roughly doubling from 0.8 percent in 2021 to 1.7 percent in 2025, while every other product declined.
Both statements are accurate. Year over year, youth pouch use held steady. Across five years, it doubled while the rest of the market shrank. Among students who currently use pouches, FDA reports that 26.3 percent used them on at least 20 of the past 30 days, and 90.8 percent used flavored pouches, with mint the most popular flavor.
Advocacy Groups Are Objecting to the Review Process as Much as the Product
The American Lung Association framed its objection around flavors. Ranjana Caple, the group's director of federal advocacy, said in a statement to The National News Desk that every new flavored tobacco product authorized by FDA is another gamble with kids' health, adding that over 90 percent of young people who use nicotine pouches use flavored products.
The American Heart Association raised a procedural objection. The association said the authorization was made under an ill-defined nicotine pouch 'pilot program' that the FDA announced it was ending earlier this year, and that key questions about the program remain unanswered, including how it differed from the existing premarket review pathway and whether evaluation standards changed. The group called on FDA to prohibit the sale of all flavored tobacco products, including menthol.
FDA describes the pilot differently, saying it streamlined review processes, produced faster resolution of issues and shorter applicant response times, and that the agency has begun applying those efficiencies to other applications.
The disagreement is therefore not primarily about whether pouches deliver fewer toxicants than cigarettes. It is about whether a faster review pathway applied to flavored products adequately weighed the youth side of the statutory balance.
The Practical Picture for Families and Adults Who Smoke
The two audiences here need different information, and collapsing them produces bad advice.
For parents, the useful step is recognition rather than alarm. Pouches leave no smell and no vapor. Signs worth noticing include small round tins, unexplained gum irritation or mouth sores, and increased irritability or difficulty concentrating, which can reflect nicotine withdrawal between uses. Nicotine can affect the developing brain in areas governing attention, learning, mood, and impulse control, and brain development continues into the mid-twenties. Researchers have also noted that standard clinical intake forms asking about smoking or vaping often miss pouch use entirely, so it is worth mentioning directly at a pediatric visit.
For adults who currently smoke, the FDA's position is that complete switching to an authorized pouch may reduce exposure to harmful chemicals, but that using both delivers much less benefit. Anyone considering pouches as a cessation route should discuss it with a clinician, since FDA-approved cessation medications and counseling have a stronger evidence base for quitting than switching products does. This article is general information and is not a treatment recommendation.
Independent researchers have also cautioned that much of the harm reduction evidence base for pouches has been industry-sponsored, that independent verification remains limited, and that long-term health outcome data does not yet exist for a product category that has been on the US market for only about a decade.
FDA is continuing annual youth tobacco surveillance, and the next release will provide the first read on whether the expanded authorized flavor list coincides with any change in youth uptake. That is the next meaningful checkpoint.
Frequently Asked Questions
What did FDA authorize? Four on! Nicotine pouch products from Helix Innovations: Rich Berry 2 milligrams, Cappuccino 2 milligrams, Cappuccino 4 milligrams and Autumn Spice 2 milligrams.
Does authorization mean these are safe? No. FDA states that all tobacco products are harmful and potentially addictive and that non-users should not start.
Is youth pouch use rising? FDA found it stable at 1.7 percent between 2024 and 2025. A separate analysis found it roughly doubled since 2021 while other products declined.
How many pouches has FDA authorized overall? Thirty products to date.
Why do heart and lung groups object? They argue flavors drive youth uptake and that the pilot review program used for these products was never adequately explained.
How can a parent tell if a teen is using pouches? There is no smell or vapor. Look for small round tins, gum irritation or mouth sores, and mention pouches specifically to a pediatrician.
Are pouches an approved way to quit smoking? No. They are authorized tobacco products, not approved cessation therapies. Discuss quitting options with a clinician.
